Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: Impact of CYP2D6 genotype on the hydroxylation of nortriptyline

Journal of Clinical Psychopharmacology

Volumn 20, Issue 2, 2000, Pages 141-149

  Morita, Sachiyo ^a   Shimoda, Kazutaka ^a   Someya, Toshiyuki ^b   Yoshimura, Yoshitaka ^c   Kamijima, Kunitoshi ^c   Kato, Nobumasa ^d  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; NORTRIPTYLINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG HYDROXYLATION; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; JAPAN; MALE; PRIORITY JOURNAL; STEADY STATE;

ADJUSTMENT DISORDERS; ADOLESCENT; ADULT; AGED; ALLELES; BIPOLAR DISORDER; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER, MAJOR; DNA MUTATIONAL ANALYSIS; ETHNIC GROUPS; FEMALE; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; NORTRIPTYLINE;

EID: 0034115770     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200004000-00005     Document Type: Article

References (55)

1. Hammer W, Sjöqvist F. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci 1967;6:1895-903.
2. Alexanderson B, Evans DA, Sjöqvist F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J 1969;4:764-8.
3. Alexanderson B, Borgå O. Urinary excretion of nortriptyline and five of its metabolites in man after single and multiple oral dose. Eur J Clin Pharmacol 1973;5:174-80.
4. Bertilsson L, Alexanderson B. Stereospecific hydroxylation of nortriptyline in man in relation to interindividual differences in its steady state plasma levels. Eur J Clin Pharmacol 1972;4:201-5.
5. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;2:584-6.
6. Tucker GT, Silas JH, Iyun AO, Lennard MS, Smith AJ. Polymorphic hydroxylation of debrisoquine [letter]. Lancet 1977;2:718.
7. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979;16:183-7.
8. Bertilsson L, Eichelbaum M, Mellström B, Säwe J, Schulz HU, Sjöqvist F. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci 1980;27:1673-7.
9. Mellström B, Bertilsson L, Säwe J, Schulz HU, Sjöqvist F. E-and Z-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 1981;30:189-93.
10. Nordin C, Siwers B, Benitez J, Bertilsson L. Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients: relationship to the debrisoquine hydroxylation metabolic ratio. Br J Clin Pharmacol 1985;19:832-5.
11. Gram LF, Brøsen K, Kragh Sørensen P, Christensen P. Steady-state plasma levels of E-and Z-10-OH-nortriptyline in nortriptyline-treated patients: significance of concurrent medication and the sparteine oxidation phenotype. Ther Drug Monit 1989; 11:508-14.
12. Breyer Pfaff U, Pfandl B, Nill K, Nusser E, Monney C, Jonzier Perey M, Baettig D, Baumann P. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin Pharmacol Ther 1992;52:350-8.
13. Olesen OV, Linnet K. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos 1997;25:740-1.
14. Dahl ML, Nordin C, Bertilsson L. Enantioselective hydroxylation of nortriptyline in human liver microsomes, intestinal homogenate, and patients treated with nortriptyline. Ther Drug Monit 1991;13:189-94.
15. Pfandl B, Morike K, Winne D, Schareck W, Breyer Pfaff U. Stereo-selective inhibition of nortriptyline hydroxylation in man by quinidine. Xenobiotica 1992;22:721-30.
16. Nordin C, Bertilsson L. Active hydroxymetabolites of antidepressants: emphasis on E-10-hydroxy-nortriptyline. Clin Pharmacokinet 1995;28:26-40.
17. Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a Caucasian British population. J Med Genet 1980; 17:102-5.
18. Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533-7.
19. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, Sjöqvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-97.
20. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-8.
21. Ishizaki T, Eichelbaum M, Horai Y, Hashimoto K, Chiba K, Dengler HJ. Evidence for polymorphic oxidation of sparteine in Japanese subjects. Br J Clin Pharmacol 1987;23:482-5.
22. Lou YC, Ying L, Bertilsson L, Sjöqvist F. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet 1987;2:852-3.
23. Yue QY, Bertilsson L, Dahl Puustinen ML, Säwe J, Sjöqvist F, Johansson I, Ingelman Sundberg M. Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese [letter]. Lancet 1989;2:870.
24. Johansson I, Yue QY, Dahl ML, Heim M, Säwe J, Bertilsson L, Meyer UA, Sjöqvist F, Ingelman Sundberg M. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 1991;40:553-6.
25. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991;10:545-58.
26. Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjöqvist F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992;51:12-7.
27. Dahl ML, Bertilsson L, Nordin C. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology (Berl) 1996;123:315-9.
28. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-9.
29. Suzuki A, Otani K, Mihara K, Yasui N, Kaneko S, Inoue Y, Hayashi K. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics 1997;7:415-8.
30. Suzuki A, Otani K, Mihara K, Yasui N, Kondo T, Tokinaga N, Furukori H, Kaneko S, Inoue Y, Hayashi K. Effects of various factors including the CYP2D6 genotype and coadministration of flunitrazepam on the steady-state plasma concentrations of bromperidol and its reduced metabolites. Psychopharmacology (Berl) 1998;135:333-7.
31. Mihara K, Otani K, Suzuki A, Yasui N, Nakano H, Meng X, Ohkubo T, Nagasaki T, Kaneko S, Tsuchida S, Sugawara K, Gonzalez F. Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Psychopharmacology (Berl) 1997;133: 95-8.
32. Dahl ML, Yue QY, Roh HK, Johansson I, Säwe J, Sjöqvist F, Bertilsson L. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 1995;5:159-64.
33. Bertilsson L, Dahl ML. Polymorphic drug oxidation: relevance to the treatment of psychiatric disorders. CNS Drugs 1996;5:200-23.
34. Åsberg M, Cronholm B, Sjöqvist F, Tuck D. Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J 1971;3:331-4.
35. Braithwaite R, Montgomery S, Dawling S. Nortriptyline in depressed patients with high plasma levels, II. Clin Pharmacol Ther 1978;23:303-8.
36. Kragh-SÌrensen P, Åsberg M, Eggert-Hansen C. Plasma-nortriptyline levels in endogenous depression. Lancet 1973;1:113-5.
37. Montgomery S, Braithwaite R, Dawling S, McAuley R. High plasma nortriptyline levels in the treatment of depression, I. Clin Pharmacol Ther 1978;23:309-14.
38. Ziegler VE, Clayton PJ, Taylor JR, Co BT, Biggs JT. Nortriptyline plasma levels and therapeutic response. Clin Pharmacol Ther 1976;20:458-63.
39. Daniel W, Melzacka M. The effect of neuroleptics on imipramine demethylation in rat liver microsomes and imipramine and desipramine level in rat brain. Biochem Pharmacol 1986;35:3249-53.
40. Krüger R, Hözl G, Kuss HJ, Schefold L. Influence of neuroleptics on the metabolism of tricyclic antidepressants: in vitro experiments with rat liver microsomes. Biol Psychiatry 1986;21: 1247-57.
41. Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E. Phenobarbital induces the 2-hydroxylation of desipramine. Ther Drug Monit 1996;18:60-4.
42. Träskman L, Åsberg M, Bertilsson L, Cronholm B, Mellström B, Neckers LM, Sjöqvist F, Thoren P, Tybring G. Plasma levels of chlorimipramine and its demethyl metabolites during treatment of depression. Clin Pharmacol Ther 1979;26:600-10.
43. Bertilsson L, Aberg-Wistedt A, Liden A, Otani K, Spina E. Alprazolam does not inhibit the metabolism of nortriptyline in depressed patients or inhibit the metabolism of desipramine in human liver microsomes. Ther Drug Monit 1988;10:231-3.
44. Otani K, Nordin C, Bertilsson L. No interaction of diazepam on amitriptyline disposition in depressed patients. Ther Drug Monit 1987;9:120-2.
45. Shimoda K, Yasuda S, Morita S, Shibasaki M, Someya T, Bertilsson L, Takahashi S. Significance of monitoring plasma levels of amitriptyline, and its hydroxylated and desmethylated metabolites in prediction of the clinical outcome of depressive state. Psychiatry Clin Neurosci 1997;51:35-41.
46. Fekete J, Del Castilho P, Kraak JC. Reversed-phase liquid chromatography for the separation of chlorpromazine, imipramine and some of their metabolites. J Chromatogr 1981;204:319-27.
47. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, Gulbrandsen AK. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995;5:215-23.
48. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993;90: 11825-9.
49. Dahl ML, Johansson I, Bertilsson L, Ingelman Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population: analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995;274:516-20.
50. Dalén P, Dahl ML, Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in Caucasian persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998;63:444-52.
51. Shimoda K, Minowada T, Noguchi T, Takahashi S. Interindividual variations of desmethylation and hydroxylation of clomipramine in an Oriental psychiatric population. J Clin Psychopharmacol 1993;13:181-8.
52. Shimoda K, Noguchi T, Ozeki Y, Morita S, Shibasaki M, Someya T, Takahashi S. Metabolism of clomipramine in a Japanese psychiatric population: hydroxylation, desmethylation and glucuronidation. Neuropsychopharmacology 1995;12: 323-33.
53. Shimoda K, Noguchi T, Morita S, Ozeki Y, Shibasaki M, Someya T, Takahashi S. Interindividual variations of desmethylation and hydroxylation of amitriptyline in a Japanese psychiatric population. J Clin Psychopharmacol 1995;15:175-81.
54. Yue QY, Zhong ZH, Tybring G, Dalén P, Dahl ML, Bertilsson L, Sjöqvist F. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1998;64:384-90.
55. Jerling M, Merlé Y, Mentré F, Mallet A. Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6: an evaluation with the nonparametric maximum likelihood method. Br J Clin Pharmacol 1994;38:453-62